0001562180-20-001621.txt : 20200224
0001562180-20-001621.hdr.sgml : 20200224
20200224193223
ACCESSION NUMBER: 0001562180-20-001621
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200220
FILED AS OF DATE: 20200224
DATE AS OF CHANGE: 20200224
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAUER EUGENE A
CENTRAL INDEX KEY: 0001210524
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36668
FILM NUMBER: 20646690
MAIL ADDRESS:
STREET 1: C/O DERMIRA, INC.
STREET 2: 275 MIDDLEFIELD ROAD, SUITE 150
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dermira, Inc.
CENTRAL INDEX KEY: 0001557883
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273267680
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 275 MIDDLEFIELD ROAD
STREET 2: SUITE 150
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650 421 7200
MAIL ADDRESS:
STREET 1: 275 MIDDLEFIELD ROAD
STREET 2: SUITE 150
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-02-20
true
0001557883
Dermira, Inc.
DERM
0001210524
BAUER EUGENE A
C/O DERMIRA, INC.
275 MIDDLEFIELD ROAD, SUITE 150
MENLO PARK
CA
94025
true
true
false
false
Chief Medical Officer
Common Stock
2020-02-11
5
G
false
E
12924.00
0.00
D
3726.00
D
Common Stock
2020-02-11
5
G
false
E
10772.00
0.00
D
16206.00
I
By the Bauer Family 1995 Trust
Common Stock
2020-02-20
4
D
false
3726.00
18.75
D
0.00
D
Common Stock
2020-02-20
4
D
false
16206.00
18.75
D
0.00
I
By the Bauer Family 1995 Trust
Stock Options (Right to buy)
0.986
2020-02-20
4
D
false
110434.00
D
2021-10-03
Common Stock
110434.00
0.00
D
Stock Options (Right to buy)
0.986
2020-02-20
4
D
false
32758.00
D
2022-02-08
Common Stock
32758.00
0.00
D
Stock Options (Right to buy)
1.218
2020-02-20
4
D
false
103258.00
D
2023-01-03
Common Stock
103258.00
0.00
D
Stock Options (Right to buy)
16.00
2020-02-20
4
D
false
16332.00
D
2024-10-01
Common Stock
16332.00
0.00
D
Employee Stock Options (Right to buy)
16.00
2020-02-20
4
D
false
9528.00
D
2024-10-01
Common Stock
9528.00
0.00
D
Stock Options (Right to buy)
26.37
2020-02-20
4
D
false
52500.00
D
2026-02-04
Common Stock
52500.00
0.00
D
Employee Stock Options (Right to buy)
33.84
2020-02-20
4
D
false
48750.00
D
2027-02-16
Common Stock
48750.00
0.00
D
Employee Stock Options (Right to buy)
28.25
2020-02-20
4
D
false
57000.00
D
2028-02-14
Common Stock
57000.00
0.00
D
Employee Stock Options (Right to buy)
7.42
2020-02-20
4
D
false
65000.00
D
2029-02-11
Common Stock
65000.00
0.00
D
Restricted Stock Unit
2020-02-20
4
D
false
2437.00
D
Common Stock
2437.00
0.00
D
Restricted Stock Unit
2020-02-20
4
D
false
5700.00
D
Common Stock
5700.00
0.00
D
Restricted Stock Unit
2020-02-20
4
D
false
15000.00
D
Common Stock
15000.00
0.00
D
The Reporting Person is a Co-Trustee.
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
/s/ Andrew L. Guggenhime, by power of attorney
2020-02-24